BioStem Technologies® to Debut American Amnion(TM) at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference
MWN-AI** Summary
BioStem Technologies, Inc. (OTC: BSEM), a prominent MedTech firm specializing in placental-derived biologics for advanced wound care, is set to debut its innovative product line, American Amnion, at the Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference in Phoenix, Arizona, from December 10-13, 2025. The American Amnion product line includes two offerings: American Amnion AC, a full thickness dehydrated human amnion and chorion membrane (DHACM), and American Amnion, which comprises dehydrated human amnion membrane (DHAM). Both products serve as protective coverings for acute or chronic wounds and utilize BioStem's proprietary BioRetain® technology, enhancing the preservation of the tissue's natural properties.
Recent clinical studies underscore the effectiveness of these allografts. A randomized controlled trial published in the International Journal of Tissue Repair indicated that patients using the BioRetain-preserved amniochorion exhibited a wound closure probability of 53%, significantly outperforming the 31% benchmark of standard care. Additionally, a comparative study in Health Science Reports highlighted a 14% faster time to closure with DHACM and a 27% reduction in the number of applications required to achieve wound closure compared to a leading product.
Jason Matuszewski, CEO of BioStem, emphasized the critical need for improved care options for veterans facing chronic wounds, noting the growing utilization of placental products within the VA system. Beyond healthcare, BioStem actively supports veterans through community initiatives, such as its sponsorship of the Florida Panthers' Heroes Among Us program, honoring military veterans at home games.
Attendees at the Desert Foot Conference can explore the American Amnion line further at BioStem’s workshops and sessions, demonstrating the company's commitment to advancing standards in wound care through innovative, evidence-based solutions.
MWN-AI** Analysis
As BioStem Technologies, Inc. (OTC: BSEM) unveils its innovative American Amnion product line at the 2025 Desert Foot Conference, investors should closely examine the implications of this launch. The American Amnion AC and American Amnion allografts are optimized for advanced wound care, utilizing the proprietary BioRetain® technology. This innovation not only enhances the clinical efficacy of the products—demonstrating a significant increase in wound closure rates—but also aligns with a growing market for placental-derived biologics, particularly within the veterans' demographic.
Recent clinical studies validate BioStem’s assertions, showing marked improvements in healing times and cost efficiency compared to traditional treatment options. With a 50% increase in the use of placental-based products over the last five years in Veterans Affairs (VA) settings, the timing of this launch is crucial. BioStem is poised to capture a significant share of this underserved market segment, where chronic, non-healing wounds are prevalent.
Moreover, BioStem’s commitment to community and veteran support adds a social responsibility dimension to its business model, potentially enhancing brand loyalty and customer trust. The sponsorship of the Florida Panthers’ Heroes Among Us program is a testament to its dedication, which could further elevate its image among stakeholders, and translate into better clinical adoption rates.
Investors should consider BioStem as a compelling addition to their portfolios. The alignment of innovative product offerings with pivotal market needs, combined with a strong community outreach strategy, positions BioStem Technologies for potential growth. Monitoring ongoing clinical trial results and market adoption rates in the coming months will be essential for gauging the stock's performance and future prospects.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
POMPANO BEACH, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company specializing in placental-derived biologics for advanced wound care, today announced the launch of a new product line, American Amnion, at the Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference held in Phoenix, Arizona, on December 10-13, 2025.
American Amnion AC is a human connective tissue allograft comprised of full thickness dehydrated human amnion and chorion membrane (DHACM) including the intermediate layer, while American Amnion is comprised of dehydrated human amnion membrane (DHAM) also including the intermediate layer. Both are intended for homologous use as a protective covering for acute or chronic wounds and are produced using BioStem’s proprietary BioRetain ® technology, which optimizes the preservation of the native tissue’s innate structural and molecular composition.
Allografts produced with this technology have demonstrated superior clinical performance as documented in several recently published studies. In a multi-center randomized controlled clinical trial published in the International Journal of Tissue Repair (2025), McCoy et al. reported that patients treated with the BioRetain-preserved full thickness amniochorion product (referenced in the published manuscript as BR-AC) demonstrated a probability of wound closure (53%) that was almost twice that observed in patients treated with the standard of care (31%). Similarly, in a comparative retrospective study published in Health Science Reports (2024), Frykberg et al. documented that the BioRetain-preserved DHACM outperformed a leading competitor in both clinical and cost effectiveness, by demonstrating a 14% reduction in time to closure and requiring 27% fewer applications to achieve closure.
“Veterans represent a significantly underserved population with a disproportionately high risk of chronic, non-healing wounds. The introduction of American Amnion is a meaningful step forward in advancing the standard of care for these patients,” said Jason Matuszewski, CEO and Chairman of BioStem Technologies. “The use of placental-based products has increased by 50% over the last five years in the VA system. By bringing innovative, evidence-driven solutions to market, we are not only improving outcomes and quality of life for our veterans, but also helping our clinician partners deliver more efficient, cost-effective care.”
BioStem not only supports our veterans in the clinic, but also in the community. The Company recently became the exclusive sponsor of the Florida Panthers’ Heroes Among Us program. This program publicly recognizes the contributions of a United States military veteran before every home game at the Panthers’ Amerant Bank Arena in Sunrise, FL, near the Company’s Pompano Beach global headquarters.
Experience American Amnion at The Desert Foot Conference:
- December 11 th from 10:30 am to 1:30 pm MST at one of BioStem’s six Hands-On Workshops: Superior Science that Delivers Optimal Results: Preserving the Natural Integrity in Amniotic Tissue for Advanced Wound Care.
- December 11 th from 2:30 pm to 3:00 pm MST during the Scientific Agenda: Optimizing Preservation of Inherent Properties in Placental Membranes: Impact on Clinical Outcomes in Advanced Wound Care, Wendy Weston, PhD
About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain ® processing method. BioRetain ® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE ® , VENDAJE AC ® , VENDAJE OPTIC ® , American Amnion™, and American Amnion AC™. Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit biostemtechnologies.com and follow us on Twitter and LinkedIn .
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE , and follow us on X and LinkedIn .
Contact BioStem Technologies, Inc.:
Website: www.biostemtechnologies.com
E-Mail: info@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342
Investor Relations:
Philip Trip Taylor, Gilmartin Group
E-Mail: ir@biostemtech.com
FAQ**
What specific clinical outcomes has BioStem Technologies Inc BSEM recorded with the American Amnion products compared to other treatments in wound care?
How does BioStem Technologies Inc BSEM’s proprietary BioRetain® technology set its products apart in terms of preservation of tissue structure and effectiveness in advanced wound care?
Given the recent studies showing superior performance, what marketing strategies is BioStem Technologies Inc BSEM implementing to promote American Amnion among clinicians and healthcare facilities?
What initiatives are in place at BioStem Technologies Inc BSEM to address the growing need for wound care solutions for underserved populations, particularly veterans?
**MWN-AI FAQ is based on asking OpenAI questions about BioStem Technologies Inc (OTC: BSEM).
NASDAQ: BSEM
BSEM Trading
-10.85% G/L:
$5.1886 Last:
50,334 Volume:
$5.71 Open:
